Citigroup’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-7,289
| Closed | -$27K | – | 7802 |
|
|
2017
Q4 | $27K | Buy |
7,289
+5,269
| +261% | +$21.6K | ﹤0.01% | 6582 |
|
|
2017
Q3 | $8K | Buy |
2,020
+1,793
| +790% | +$6.86K | ﹤0.01% | 6767 |
|
|
2017
Q2 | $1K | Buy |
227
+69
| +44% | +$274 | ﹤0.01% | 7292 |
|
|
2017
Q1 | $1K | Sell |
158
-33
| -17% | -$139 | ﹤0.01% | 7149 |
|
|
2016
Q4 | $1K | Sell |
191
-3,541
| -95% | -$22.9K | ﹤0.01% | 7152 |
|
|
2016
Q3 | $37K | Buy |
3,732
+1,751
| +88% | +$12.4K | ﹤0.01% | 5869 |
|
|
2016
Q2 | $11K | Sell |
1,981
-13,143
| -87% | -$89.2K | ﹤0.01% | 6525 |
|
|
2016
Q1 | $115K | Buy |
15,124
+6,584
| +77% | +$50.7K | ﹤0.01% | 5572 |
|
|
2015
Q4 | $114K | Buy |
8,540
+8,471
| +12,277% | +$146K | ﹤0.01% | 5280 |
|
|
2015
Q3 | $1K | Sell |
69
-327
| -83% | -$6.7K | ﹤0.01% | 7283 |
|
|
2015
Q2 | $8K | Sell |
396
-549
| -58% | -$8.68K | ﹤0.01% | 6601 |
|
|
2015
Q1 | $9K | Sell |
945
-1,448
| -61% | -$14.2K | ﹤0.01% | 6523 |
|
|
2014
Q4 | $27K | Sell |
2,393
-3,394
| -59% | -$36.8K | ﹤0.01% | 6076 |
|
|
2014
Q3 | $67K | Buy |
5,787
+334
| +6% | +$5.1K | ﹤0.01% | 5078 |
|
|
2014
Q2 | $106K | Sell |
5,453
-223
| -4% | -$3.93K | ﹤0.01% | 4627 |
|
|
2014
Q1 | $102K | Sell |
5,676
-152
| -3% | -$2.5K | ﹤0.01% | 4973 |
|
|
2013
Q4 | $62K | Sell |
5,828
-2,017
| -26% | -$22.5K | ﹤0.01% | 5602 |
|
|
2013
Q3 | $97K | Buy |
7,845
+2,050
| +35% | +$21.6K | ﹤0.01% | 4752 |
|
|
2013
Q2 | $54K | Buy |
+5,795
| New | +$74.4K | ﹤0.01% | 5335 |
|
Citigroup's CASC Position: Q1 2018 in Review
Citigroup sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 7,289 shares — an estimated $27K sold.
Citigroup first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $115K in Q1 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Citigroup reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Citigroup sold 7,289 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $27K.
- Citigroup first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Citigroup's Cascadian Therapeutics, Inc. position peaked at $115K in Q1 2016.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.